These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 2147637

  • 1. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, Anderson DC.
    Diabet Med; 1990; 7(8):736-43. PubMed ID: 2147637
    [Abstract] [Full Text] [Related]

  • 2. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN, Winocour PH, Bhatnagar D.
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [Abstract] [Full Text] [Related]

  • 3. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 4. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
    Jeck T, Riesen WF, Keller U.
    Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
    [Abstract] [Full Text] [Related]

  • 5. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH, Durrington PN, Bhatagnar D, Ishola M, Mackness M, Arrol S, Anderson DC.
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [Abstract] [Full Text] [Related]

  • 6. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 7. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 8. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M, Kuroda Y, Terao M, Yaginuma T, Kawakami M, Kanazawa Y.
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients.
    Niort G, Cassader M, Gambino R, Pagano G.
    Diabete Metab; 1992 Apr; 18(3):221-8. PubMed ID: 1397477
    [Abstract] [Full Text] [Related]

  • 10. A therapeutic trial of bezafibrate on patients with hyperlipidemia with or without diabetes mellitus.
    Ho LT, Chiang HL, Tsai H, Chou TY, Kwok CF.
    Proc Natl Sci Counc Repub China B; 1984 Jul; 8(3):240-5. PubMed ID: 6571590
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
    Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD.
    Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
    [Abstract] [Full Text] [Related]

  • 12. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J, Schwartz S, Brunner D.
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [Abstract] [Full Text] [Related]

  • 13. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D, Oschry Y, Fainaru M, Eisenberg S.
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [Abstract] [Full Text] [Related]

  • 14. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
    Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori CR, Tremoli E.
    Eur J Clin Pharmacol; 1992 Feb; 43(3):219-23. PubMed ID: 1425883
    [Abstract] [Full Text] [Related]

  • 15. Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin.
    Sinzinger H, Pirich C, Kondor P, Etti H.
    Eur Heart J; 1995 Nov; 16(11):1491-501. PubMed ID: 8881840
    [Abstract] [Full Text] [Related]

  • 16. Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial.
    Johnston GD, Vyssoulis G, Feely J, Holden RD, Radley DR.
    J Hum Hypertens; 1995 Feb; 9(2):123-9. PubMed ID: 7752174
    [Abstract] [Full Text] [Related]

  • 17. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Prager R, Schernthaner G, Kostner GM, Mühlhauser I, Zechner R, Dorda W.
    Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
    [Abstract] [Full Text] [Related]

  • 18. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
    Vázquez-Chávez C, Salinas-Orozco S, Gómez-Díaz RA, Rosso-Juárez MM, Moreno-Vázquez K, Nissen-Torres T, Argüero-Sánchez R.
    Rev Invest Clin; 1998 Jun; 50(6):491-6. PubMed ID: 10070221
    [Abstract] [Full Text] [Related]

  • 19. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A, de Vries R, van Leeuwen JJ, Gautier T, van Pelt LJ, Tselepis AD, Lagrost L, Dullaart RP.
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [Abstract] [Full Text] [Related]

  • 20. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI, Bhatnagar D, Durrington PN, Prais H, Haynes B, Morgan J, Borthwick L.
    Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.